文献速递临床试验与 GCP

中药治疗慢性阻塞性肺疾病急性加重患者的随机对照试验研究方案

Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-12-16

该研究为多中心、双盲、平行组随机对照试验,计划纳入378例慢性阻塞性肺疾病急性加重(AECOPD)患者,按1:1随机分为中药组与中药安慰剂组,在健康教育与常规治疗基础上分别给予中药或安慰剂(10 g/包,每日两次),双盲治疗2周并随访4周,主要结局为COPD评估测试(CAT)。

要点

  • 在多中心双盲RCT中评估中药治疗AECOPD的疗效
  • 计划纳入378例AECOPD患者,按1:1随机分组
  • 主要结局为CAT,次要结局涵盖治疗失败率、住院时间、再入院率等

核心结论

  • 该研究方案旨在通过高质量随机对照试验验证中药治疗AECOPD的有效性,为制定中药治疗方案提供证据。

研究设计与样本

  • 多中心、双盲、平行组随机对照试验,计划随机分配378例AECOPD患者,按1:1比例分为两组。
  • 干预组在健康教育与常规治疗基础上给予中药,对照组按中医证型给予中药安慰剂,10 g/包,每日两次。
  • 双盲治疗持续2周,随后随访4周,在基线、治疗2周后及4周随访时记录结局。

关键数值与推荐

  • 主要结局为COPD评估测试(CAT)。
  • 次要结局包括治疗失败率、治疗成功率、住院时间、AECOPD再入院率、插管率、死亡率、呼吸困难、36项简短健康调查(SF-36)及COPD患者报告结局量表。

临床怎么用

  • 若试验证实有效,可为AECOPD患者在常规治疗基础上联合中药治疗提供随机对照证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence, mortality, and prevalence of chronic obstructive pulmonary disease (COPD) are high in China. Acute exacerbations of COPD (AECOPD) are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression. AECOPD have been effectively treated with Chinese medicine for a long time. The aim of this proposed trial is to assess the therapeutic effect of Chinese medicine (CM) on AECOPD. METHODS/DESIGN: This proposed study is a multicenter, double-blind, parallel-group randomized controlled trial (RCT). We will randomly assign 378 participants with AECOPD into two groups in a 1:1 ratio. On the basis of health education and conventional treatment, the intervention group will be treated with CM, and the control group is given CM placebo according to CM syndrome. Patients are randomized to either receive CM or placebo, 10 g/packet, twice daily. The double-blind treatment lasts for 2 weeks and is followed up for 4 weeks. The main outcome is the COPD Assessment Test; secondary outcomes are treatment failure rate, treatment success rate, length of hospital stay, AECOPD readmission rate, intubation rate, mortality, dyspnea, the 36-item Short Form Health Survey, and the COPD patient-reported outcome scale. We will document these outcomes faithfully at the beginning of the study, 2 weeks after treatment, and at the 4 weeks follow-up. DISCUSSION: This high-quality RCT with strict methodology and few design deficits will help to prove the effectiveness of CM for AECOPD. We hope this trial will provide useful evidence for developing a therapeutic schedule with CM for patients with AECOPD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03428412. Registered on 4 February 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang H, Li J, Yu X, et al. Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31842969. doi:10.1186/s13063-019-3772-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。